AdvaMed Pans CMS Plan To Mandate Publicizing Hospital Rates, But Likes Pay Path For Breakthrough Devices
• By Sue Darcey
AdvaMed took issue with several aspects of a US Centers for Medicare and Medicaid Services (CMS) outpatient payment system draft rule mandating that hospitals publicize prices for their surgical procedures and laboratory tests, in comments on the draft. But the medtech industry advocacy group, as well as the Medical Device Manufacturers Association (MDMA), say they support another provision – the agency's new Medicare coverage and payment proposal for breakthrough devices – and requested only minor tweaks to the plan.
AdvaMed has criticized a 2020 Medicare Outpatient Prospective Payment System (OPPS) proposal mandating that hospitals publicly post prices for their 300 most-frequently used procedure costs and lab tests.
The medtech industry advocacy group commented that the transparency plan laid out in the draft OPPS rule issued by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
A federal court in Illinois ruled against SurModics and BC Holdings' request for FDA documents to support a proposed merger. The FTC has challenged the merger, claiming it threatens competition in hydrophilic device coatings. The ruling may indicate the FTC is likely to succeed.
An “NHS Innovator Passport” that allows quicker uptake of proven technologies across the national healthcare provider is one of the wins the UK government is looking to score from its new Life Sciences Sector plan. The plan majors on prevention. The medtech industry has given it a cautious welcome.
The exemption, which President Donald Trump announced on July 17, is intended to cut the risk of critical device shortages. Stakeholders say the technology needed to cut emissions to required levels is not yet widely available.
Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.
The exemption, which President Donald Trump announced on July 17, is intended to cut the risk of critical device shortages. Stakeholders say the technology needed to cut emissions to required levels is not yet widely available.
Dexcom has recalled several models of its glucose monitoring receivers due to a speaker glitch that may suppress vital blood sugar alerts. The FDA designated the recall, which affects thousands of devices, as class I.
Worldwide medtech sales totaled $8.5bn in Q2, up 6.1%. Sales grew 8% in the US and 4.1% outside the US. Cardiovascular, surgery and vision were the primary growth drivers. Acquisitions and divestitures had net positive impact of 200 basis points, largely due to the acquisition of Shockwave Medical.